AstraZeneca Vietnam and The Cancer Patient Support Fund - Bright Future (Bright Future Fund) recently signed a Memorandum of Understanding (MOU) to collaborate on comprehensive healthcare for cancer patients and to promote healthcare equity in Vietnam.
AstraZeneca Vietnam and Bright Future Fund cooperate to advance comprehensive healthcare and health equity in Vietnam
The signing event was attended by Assoc. Prof. Dr. Nguyen Thi Xuyen, Chair of the Bright Future Fund; Atul Tandon, General Director of AstraZeneca Vietnam; members of the Fund’s Board of Management; and other relevant stakeholders.
According to GLOBOCAN 20221, Vietnam estimated 180,480 new cancer cases and 120,184 cancer deaths. Breast, liver, and lung cancers were the most prevalent, with rising incidence and mortality rates.
While advancements in science, government support, and collaboration effort of the Ministry of Health with businesses, and healthcare organizations have expanded access to cancer treatments through health insurance coverage, challenges still persist. Over 70% of Vietnamese cancer patients are diagnosed at late stages, leading to lower survival rates compared to developed countries.
Cancer patients also require comprehensive care, including nutrition, psychological support, physical activity, and adverse event management, to enhance treatment outcomes and extend life expectancy.
Therefore, this MOU will extend the long-standing cooperation between AstraZeneca and the Bright Future Fund, simultaneously promoting programmemes and initiatives aimed at comprehensive patient care, early screening awareness, improved treatment access, and enhanced quality of life for cancer patients. Ultimately, this collaboration contributes to achieving healthcare equity and aims to eliminate cancer as a leading cause of death in Vietnam.
